TY - JOUR
T1 - Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States
AU - Verstovsek, Srdan
AU - Yu, Jingbo
AU - Scherber, Robyn M.
AU - Verma, Sumit
AU - Dieyi, Christopher
AU - Chen, Chien Cheng
AU - Parasuraman, Shreekant
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - This analysis examined trends in incidence and survival among US adults with myeloproliferative neoplasms, including essential thrombocythemia (ET; n = 14,676), polycythemia vera (PV; n = 15,141), and primary myelofibrosis (PMF; n = 4214), using Surveillance, Epidemiology, and End User Results (SEER) data (SEER 18; 2002–2016). Incidence and survival rates over the study period and by diagnosis year (per 5-year time frames: 2002–2006; 2007–2011; 2012–2016) were assessed. The overall incidence rates (95% CI) were 1.55 (1.52–1.57) for ET, 1.57 (1.55–1.60) for PV, and 0.44 (0.43–0.45) per 100,000 person-years for PMF, with rising ET incidence. Five-year mortality over the study period was 19.2%, 19.0%, and 51.0% for ET, PV, and PMF, respectively. Improved survival over time was observed for PV and PMF, but not for ET. These findings highlight the need for effective ET therapies, as ET incidence has risen without concurrent improvements in survival over the past 2 decades.
AB - This analysis examined trends in incidence and survival among US adults with myeloproliferative neoplasms, including essential thrombocythemia (ET; n = 14,676), polycythemia vera (PV; n = 15,141), and primary myelofibrosis (PMF; n = 4214), using Surveillance, Epidemiology, and End User Results (SEER) data (SEER 18; 2002–2016). Incidence and survival rates over the study period and by diagnosis year (per 5-year time frames: 2002–2006; 2007–2011; 2012–2016) were assessed. The overall incidence rates (95% CI) were 1.55 (1.52–1.57) for ET, 1.57 (1.55–1.60) for PV, and 0.44 (0.43–0.45) per 100,000 person-years for PMF, with rising ET incidence. Five-year mortality over the study period was 19.2%, 19.0%, and 51.0% for ET, PV, and PMF, respectively. Improved survival over time was observed for PV and PMF, but not for ET. These findings highlight the need for effective ET therapies, as ET incidence has risen without concurrent improvements in survival over the past 2 decades.
KW - Essential thrombocythemia
KW - incidence
KW - myeloproliferative neoplasms
KW - polycythemia vera
KW - primary myelofibrosis
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85125552866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125552866&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1992756
DO - 10.1080/10428194.2021.1992756
M3 - Article
C2 - 34689695
AN - SCOPUS:85125552866
SN - 1042-8194
VL - 63
SP - 694
EP - 702
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -